US equities
|
MU
$928.79
▼-2.56%
NVDA
$222.26
▼-2.74%
AAPL
$344.26
▲+0.88%
AMD
$571.75
▼-5.58%
META
$739.10
▼-3.07%
TSLA
$366.52
▼-2.32%
SPCX
$153.47
▼-1.96%
SNDK
$1,419.49
▼-4.24%
MU
$928.79
▼-2.56%
NVDA
$222.26
▼-2.74%
AAPL
$344.26
▲+0.88%
AMD
$571.75
▼-5.58%
META
$739.10
▼-3.07%
TSLA
$366.52
▼-2.32%
SPCX
$153.47
▼-1.96%
SNDK
$1,419.49
▼-4.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
87.19
+0.58 (+0.67%)
Delayed Quote
Updated: 12:43 PM EDT, Oct 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
October 13, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
September 22, 2026
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
September 10, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
↗
September 02, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals...
Via
Benzinga
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today
↗
August 31, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals...
Via
Benzinga
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
↗
August 26, 2026
Duquesne Family Office has beefed up its healthcare holdings.
Via
The Motley Fool
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
August 24, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
↗
August 23, 2026
Could this little-known biotech be a hidden gem?
Via
The Motley Fool
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
August 17, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
↗
August 17, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through...
Via
MarketBeat
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
IMCIVREE revenue surged 19% sequentially as HO patient adoption accelerated post-approval.
Via
The Motley Fool
Topics
Earnings
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or
August 11, 2026
-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
August 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
↗
August 04, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company...
Via
MarketBeat
Topics
Earnings
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call
↗
August 04, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to...
Via
Benzinga
Topics
Earnings
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
August 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
August 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
July 08, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
June 15, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
June 13, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
June 12, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
May 29, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
May 28, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
May 12, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
My Top 3 Stocks to Buy in May
↗
May 07, 2026
Forget "sell in May and go away." These stocks are good picks to buy and hold.
Via
The Motley Fool
Topics
Earnings
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
↗
May 06, 2026
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.
Via
Benzinga
Rhythm (RYTM) Q1 2026 Earnings Call Transcript
↗
May 06, 2026
Rhythm (RYTM) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
May 06, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
